Poly(ADP-ribose) Polymerase Inhibitor Combinations in First-Line Metastatic Castration-Resistant Prostate Cancer: Increasing Toxicity With Unclear Benefits-Reference-Cited by-同舟云学术

Poly(ADP-ribose) Polymerase Inhibitor Combinations in First-Line Metastatic Castration-Resistant Prostate Cancer: Increasing Toxicity With Unclear Benefits

Published:2023-12-20 Issue:36 Volume:41 Page:5501-5504
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Madan Ravi A.¹^ORCID,Karzai Fatima¹^ORCID,VanderWeele David J.²^ORCID,Cheng Heather H.³^ORCID,de Bono Johann S.⁴⁵^ORCID

Affiliation:

1. Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD

2. Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL

3. Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA

4. The Institute of Cancer Research, London, United Kingdom

5. The Royal Marsden NHS Foundation Trust, London, United Kingdom

Abstract

Positive phase III trials are not truly practice changing if they do not accurately inform on the best options for patients

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.23.01502

Reference27 articles.

1. Integrative Clinical Genomics of Advanced Prostate Cancer

2. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

3. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

4. Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

5. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enzalutamide inhibits PEX10 function and sensitizes prostate cancer cells to ROS activators;Cell Death & Disease;2024-08-03

2. Acute BRCAness Induction and AR Signaling Blockage through CDK12/7/9 Degradation Enhances PARP Inhibitor Sensitivity in Prostate Cancer;2024-07-10

3. Progression-free survival end points in prostate cancer: are we truly making progress;Nature Reviews Urology;2024-06-17

4. Androgen receptor, PARP signaling, and tumor microenvironment: the ‘perfect triad’ in prostate cancer?;Therapeutic Advances in Medical Oncology;2024-01